--- title: "REG - Morgan Stanley & Co. Oxford Biomedica PLC - Form 8.5 (EPT/RI)-Oxford Biomedica plc" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/273350761.md" description: "Morgan Stanley & Co. International plc disclosed its dealings in Oxford Biomedica plc's securities under Rule 8.5 of the Takeover Code. On January 21, 2026, the firm purchased 99,507 ordinary shares at prices ranging from £8.59 to £8.92 and sold 27,223 shares at similar prices. Additionally, it reported various cash-settled derivative transactions, including increasing and reducing long and short positions in ordinary shares. The disclosure was made on January 22, 2026, by Claire Gordon, with contact details provided for further inquiries." datetime: "2026-01-22T09:33:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273350761.md) - [en](https://longbridge.com/en/news/273350761.md) - [zh-HK](https://longbridge.com/zh-HK/news/273350761.md) --- > 支持的语言: [English](https://longbridge.com/en/news/273350761.md) | [繁體中文](https://longbridge.com/zh-HK/news/273350761.md) # REG - Morgan Stanley & Co. Oxford Biomedica PLC - Form 8.5 (EPT/RI)-Oxford Biomedica plc RNS Number : 9553P Morgan Stanley & Co. Int'l plc 22 January 2026 FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1\. KEY INFORMATION (a) Name of exempt principal trader: Morgan Stanley & Co. International plc (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Oxford Biomedica plc (c) Name of the party to the offer with which exempt principal trader is connected: EQT Fund Management S.a.r.l. (d) Date dealing undertaken: 21 January 2026 (e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state "N/A" N/A 2\. DEALINGS BY THE EXEMPT PRINCIPAL TRADER Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchases/ sales Total number of securities Highest price per unit paid/received Lowest price per unit paid/received 50p ordinary PURCHASES 99,507 8.9200 GBP 8.5900 GBP 50p ordinary SALES 27,223 8.9200 GBP 8.5905 GBP (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit 50p ordinary CFD increasing a long position 1 8.6800 GBP 50p ordinary CFD increasing a long position 202 8.7500 GBP 50p ordinary CFD increasing a long position 55 8.7738 GBP 50p ordinary CFD increasing a long position 655 8.8337 GBP 50p ordinary CFD increasing a long position 1,892 8.8849 GBP 50p ordinary CFD increasing a short position 100 8.6006 GBP 50p ordinary CFD increasing a short position 417 8.7500 GBP 50p ordinary CFD increasing a short position 156 8.7500 GBP 50p ordinary CFD increasing a short position 221 8.7500 GBP 50p ordinary CFD increasing a short position 506 8.7506 GBP 50p ordinary CFD increasing a short position 1,067 8.7783 GBP 50p ordinary CFD increasing a short position 699 8.7783 GBP 50p ordinary CFD increasing a short position 800 8.8174 GBP 50p ordinary CFD increasing a short position 70 8.8600 GBP 50p ordinary CFD increasing a short position 2,194 8.8736 GBP 50p ordinary CFD increasing a short position 11 8.8800 GBP 50p ordinary CFD reducing a long position 1 8.5900 GBP 50p ordinary CFD reducing a long position 583 8.7088 GBP 50p ordinary CFD reducing a long position 504 8.7308 GBP 50p ordinary CFD reducing a long position 67,035 8.7500 GBP 50p ordinary CFD reducing a long position 533 8.7500 GBP 50p ordinary CFD reducing a long position 74 8.7500 GBP 50p ordinary CFD reducing a long position 234 8.7500 GBP 50p ordinary CFD reducing a long position 2,096 8.7560 GBP 50p ordinary CFD reducing a long position 306 8.7686 GBP 50p ordinary CFD reducing a long position 3,972 8.7955 GBP 50p ordinary CFD reducing a long position 143 8.8582 GBP 50p ordinary CFD reducing a short position 1,904 8.7246 GBP 50p ordinary CFD reducing a short position 1,431 8.7500 GBP 50p ordinary CFD reducing a short position 112 8.7500 GBP 50p ordinary CFD reducing a short position 39 8.7800 GBP 50p ordinary CFD reducing a short position 400 8.8045 GBP 50p ordinary CFD reducing a short position 141 8.8289 GBP 50p ordinary CFD reducing a short position 1,000 8.8453 GBP 50p ordinary CFD reducing a short position 950 8.8495 GBP 50p ordinary CFD reducing a short position 3 8.9000 GBP 50p ordinary CFD reducing a short position 520 8.9200 GBP (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security N/A Product description e.g. call option N/A Writing, purchasing, selling, varying etc. N/A Number of securities to which option relates N/A Exercise price per unit N/A Type e.g. American, European etc. N/A Expiry date N/A Option money paid/ received per unit N/A (ii) Exercise Class of relevant security N/A Product description e.g. call option N/A Exercising/ exercised against N/A Number of securities N/A Exercise price per unit N/A (d) Other dealings (including subscribing for new securities) Class of relevant security N/A Nature of dealing e.g. subscription, conversion N/A Details N/A Price per unit (if applicable) N/A 3\. OTHER INFORMATION (a) Indemnity and other dealing arrangements - Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" - NONE (b) Agreements, arrangements or understandings relating to options or derivatives - Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state "none" - NONE Date of disclosure: 22 January 2026 Contact name: Claire Gordon Telephone number: +44 141 245-8893 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0) 20 7638 0129. The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END FERPPUBPGUPQUBP ### 相关股票 - [Oxford BioMedica plc (OXB.UK)](https://longbridge.com/zh-CN/quote/OXB.UK.md) ## 相关资讯与研究 - [Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role](https://longbridge.com/zh-CN/news/281052340.md) - [REG - Morgan Stanley & Co. Oxford Biomedica PLC - Form 8.5 (EPT/RI) - Oxford Biomedica plc](https://longbridge.com/zh-CN/news/275442476.md) - [Heathrow passenger fees capped as watchdog rejects funding plan](https://longbridge.com/zh-CN/news/281146321.md) - [REG - Morgan Stanley & Co. Oxford Biomedica PLC - Form 8.5 (EPT/RI) - Oxford Biomedica plc](https://longbridge.com/zh-CN/news/275106736.md) - [REG - Morgan Stanley & Co. Oxford Biomedica PLC - Form 8.5 (EPT/RI) - Oxford Biomedica plc](https://longbridge.com/zh-CN/news/274797289.md)